367272-52-4

Usage

Uses

1. Used in Pharmaceutical Applications:
Hydrochloride of (S)-2-amino-6-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid is used as a protected form of D-Lysine for the synthesis of various pharmaceutical compounds. The application reason is that D-Lysine has the ability to reduce non-enzymatic glycation in vitro, which can be beneficial in the development of drugs targeting glycation-related diseases.
2. Used in Drug Delivery Systems:
In the field of drug delivery, hydrochloride of (S)-2-amino-6-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid is used as a potential polymeric drug carrier. The application reason is that D-Lysine exists as polypeptide chains of poly-D-lysine, which is a nonspecific adhesion-promoting molecule, making it a suitable candidate for drug delivery applications.
3. Used in Research and Development:
Hydrochloride of (S)-2-amino-6-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid is also used in research and development for the study of its chemical properties and potential applications in various industries. The application reason is to explore the compound's potential in areas such as pharmaceuticals, drug delivery, and other related fields.

Upstream product

• 84624-27-1 Boc-Lys(Fmoc)-OH 

Downstream Products

• 1596360-18-7 9H-fluoren-9-ylmethyl N-[(5S)-5-cyano-5-(tritylamino)pentyl]carbamate 
• 1596360-42-7 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[2,5-dioxo-4-(4-phenoxyphenyl)piperazin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-40-5 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[3-(4-fluorophenyl)-2-oxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-35-8 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[2,5-dioxo-3-[4-(4-pyridylmethoxy)phenyl]imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-34-7 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[3-[4-(4-methoxyphenoxy)phenyl]-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-33-6 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[2,5-dioxo-3-(4-phenoxyphenyl)imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-24-5 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[2,5-dioxo-3-(4-sulfamoylphenyl)imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-23-4 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[2,5-dioxo-3-(4-propylphenyl)imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-22-3 N-[(1S)-5-Amino-1-cyano-pentyl]-6-[[3-(4-methoxyphenyl)-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-21-2 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[3-(4-fluorophenyl)-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 

Relevant academic research and scientific papers

Double-acylated GLP-1 derivatives

The invention relates to a derivative of a GLP-1 peptide, which peptide comprises a first K residue and a second K residue, at positions corresponding to position 26, and 34, respectively, of GLP-1(7-37) (SEQ ID NO:1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which y is an integer in the range of 6-13; and the linker comprises Chem. 3a: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.

Double-acylated GLP-1 derivatives

The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, which is connected at its CO—* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.